Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
Company remains committed to ongoing public dialogue on the clinical evidence supporting SYD-101 and the real-world challenges facing children, families, and eye care professionals DEL MAR, Calif., July 13, 2026 [Del Mar, California] — Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced that the U.S. Food and […]